Jove
Visualize
Contact Us

Related Experiment Videos

NCX4016: a novel antithrombotic agent.

P Gresele1, S Momi, A M Mezzasoma

  • 1Division of Internal and Cardiovascular Medicine, Department of Internal Medicine, University of Perugia, Via Enrico dal Pozzo, 06126 Perugia, Italy. grespa@unipg.it

Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
|July 9, 2003
PubMed
Summary

Nitroaspirin shows promise as a novel antithrombotic agent, inhibiting platelet aggregation and preventing restenosis in preclinical models. Further clinical studies are needed to confirm its therapeutic potential compared to existing treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-on-treatment platelet reactivity predicts adverse outcome after carotid artery stenting: A prospective study.

Thrombosis research·2023
Same author

The role of platelets, neutrophils and endothelium in COVID-19 infection.

Expert review of hematology·2022
Same author

Platelets and Matrix Metalloproteinases: A Bidirectional Interaction with Multiple Pathophysiologic Implications.

Hamostaseologie·2021
Same author

Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry.

International journal of cardiology·2020
Same author

Nitric oxide-enhancing or -releasing agents as antithrombotic drugs.

Biochemical pharmacology·2019
Same author

Laboratory monitoring of P2Y<sub>12</sub> inhibitors: communication from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2018
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Cardiovascular pharmacology
  • Thrombosis research
  • Drug discovery

Background:

  • Current antithrombotic treatments have limitations, driving the need for improved agents.
  • Nitric oxide (NO) possesses biological activities with potential antithrombotic effects.
  • Aspirin is a widely used antiplatelet drug with known limitations.

Purpose of the Study:

  • To investigate the antithrombotic and anti-proliferative effects of nitroaspirin.
  • To compare the efficacy of nitroaspirin with aspirin in preclinical models.
  • To assess the potential of nitroaspirin as an improved antithrombotic therapy.

Main Methods:

  • In vitro studies assessing platelet aggregation and adhesion under shear conditions.
  • In vitro assessment of smooth muscle cell proliferation.

Related Experiment Videos

  • In vivo studies in hypercholesterolemic mice to evaluate antithrombotic properties and prevention of restenosis.

    • Main Results:

    • Nitroaspirin inhibited platelet aggregation and adhesion under shear conditions in vitro.
    • Nitroaspirin inhibited smooth muscle cell proliferation in vitro, an effect not seen with aspirin.
    • In vivo, nitroaspirin demonstrated antithrombotic properties and prevented restenosis in hypercholesterolemic mice, where aspirin was ineffective.

    Conclusions:

    • Nitroaspirin exhibits significant advantages over aspirin and current antiplatelet agents in preclinical settings.
    • The findings suggest nitroaspirin has considerable potential for antithrombotic therapy.
    • Clinical trials are essential to determine if nitroaspirin represents a significant advancement in antithrombotic treatment.